Updated label for Daklinza for the treatment of chronic hepatitis C genotype 3 approved by the EC

Daklinza in combination with sofosbuvir is the first 12-week all-oral therapy for genotype 3 patients without cirrhosis in Europe
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Pharmacogenetics Legislation & regulation Hepatic disorders Patient care ALLY-3 cirrhosis combination daklinza genotype 3 chronic hepatitis C hcv Latest News ribaviri Source Type: news